王艺瑾副教授、博士生导师


wangyj3@sustech.edu.cn
进入个人主页返回到师资列表
个人简介王艺瑾，南方科技大学医学院副教授，博士生导师。2012 年和 2016 年分别于荷兰瓦赫宁根大学与研究中心、荷兰伊拉斯姆斯大学医学中心获得硕士和博士学位。美国伊利诺伊大学访问****。王艺瑾在国际上较早开展戊型肝炎研究。获得博士学位后，在解放军总医院第五医学中心组建科研团队，其课题组以病毒性肝炎的转化研究为核心，重点研究戊型肝炎病毒（HEV）的病毒-宿主相互作用、病毒学和免疫学发病机制、精准诊断、预后判断及抗病毒治疗策略。王艺瑾团队在戊型肝炎领域的研究处于国际领先水平。其研究方向还扩展到丙型肝炎病毒（HCV）、乙型肝炎病毒（HBV）新型冠状病毒（SARS-CoV-2）、以及非感染性肝病的临床研究。同时依托感染性疾病的研究，揭示天然免疫应答新机制。
2019 年入选北京市科技新星计划，入选解放军总医院“3+1”创新人才建设工程新秀人才，入选解放军总医院优青培育计划；曾承担多项荷兰科技部项目及荷兰肝肠病协会课题基金，现主持国家自然科学基金 2 项， 参与国家科技重大专项等项目； 近五年发表 SCI 论文 37 篇，总影响因子 260 余分，其中第一/通讯作者 15 篇，包括Lancet Respiratory Medicine，Gastroenterology，Journal of Hepatology， EbioMedicine等知名权威期刊，总影响因子 130 余分，主编英文论著 1 本；相关成果多次被三大国际肝病年会选为口头报告并获青年****奖。
研究领域其课题组以病毒感染的转化研究为核心，重点研究戊型肝炎病毒（HEV）的感染机制及开展抗病毒药物研究。通过结合最先进的分子、细胞生物学技术及多组学分析，揭示病毒-宿主的相互作用，病毒激活及逃逸天然免疫机制，并基于此开发新型高效抗病毒药物。同时通过临床大队列研究，明确HEV感染慢性化、重症化、肝外感染的危险因素，以及在特殊人群中的预后判断。同时，依托感染性疾病的研究，发现和揭示天然免疫应答新机制，重点关注于核苷酸合成抑制及线粒体功能调控。此外，其研究领域还扩展到非感染性肝病（非酒精性脂肪性肝病、肝细胞癌、胆管细胞癌）的无创诊断标志物研究。

教育背景2012/11–2016/09，荷兰伊拉斯姆斯大学医学中心，肝肠病学，博士

2010/09–2012/08，荷兰瓦赫宁根大学与研究中心，生物技术医学方向，硕士
2006/09–2010/07，南京医科大学，生物技术，学士

工作经历2020/11-至今，南方科技大学医学院，副教授
2016/09-2020/10， 解放军总医院第五医学中心，病理诊断与研究中心，副研究员



获奖情况及荣誉2020, 亚太肝病学会 （APASL）授予的旅行奖
2019， 北京市科委授予的北京市科技新星
2019， 解放军总医院授予的创新人才建设工程新秀人才
2019， 欧洲肝病学会（EASL）授予的青年****奖
2019， 中美肝病学院 优秀论文报告奖
2019， 北京医学会 北京肝病年会，优秀论文
2018, 欧洲肝病年会（EASL）授予的青年****奖
2018， 亚太肝病年会（APASL）授予的青年****奖
2018， 北京医学会 北京肝病年会，优秀论文
2017， 荷兰肝病学会（NVGE）授予的 Veldhovenbeurs 奖
2017， 中华医学会 脂肪性肝病联合学术会议,优秀论文
2017， 北京医学会 北京肝病学术年会，优秀论文
2014， 欧洲肝病年会（EASL）授予的青年****奖

杂志编委会成员2018 年 7 月 - 至今，中国研究型医院学会分子诊断医学专业委员会临床分子检验学组副组长
2018 年 7 月 - 至今，北京医学会肝病学分会肝病学分会青年委员

近年代表文章Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.
Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014; 146:1775-83.
Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.
Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.
Wang Y#, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30.
Wang Y#, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300.
Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)
Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.
Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.
Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.
Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31. (Corresponding Author)
Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.
Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. Dig Liver Dis. 2020; 52:637-43. (Co-First Author)
Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5. (Co-First Author)
Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.
Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.
Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.
Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.
Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.
Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.
Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.
Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.
Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.
Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.
Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.
Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.
Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.
Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.
Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.
Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.
Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.
Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.
Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.
Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.
Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.
Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.